SUMOylation of Rho-associated protein kinase 2 induces goblet cell metaplasia in allergic airways

Dan Tan,Meiping Lu,Yuqing Cai,Weibo Qi,Fugen Wu,Hangyang Bao,Meiyu Qv,Qiangqiang He,Yana Xu,Xiangzhi Wang,Tingyu Shen,Jiahao Luo,Yangxun He,Junsong Wu,Lanfang Tang,Muhammad Qasim Barkat,Chengyun Xu,Ximei Wu
DOI: https://doi.org/10.1038/s41467-023-39600-4
IF: 16.6
2023-07-01
Nature Communications
Abstract:Allergic asthma is characterized by goblet cell metaplasia and subsequent mucus hypersecretion that contribute to the morbidity and mortality of this disease. Here, we explore the potential role and underlying mechanism of protein SUMOylation-mediated goblet cell metaplasia. The components of SUMOylaion machinery are specifically expressed in healthy human bronchial epithelia and robustly upregulated in bronchial epithelia of patients or mouse models with allergic asthma. Intratracheal suppression of SUMOylation by 2-D08 robustly attenuates not only allergen-induced airway inflammation, goblet cell metaplasia, and hyperreactivity, but IL-13-induced goblet cell metaplasia. Phosphoproteomics and biochemical analyses reveal SUMOylation on K1007 activates ROCK2, a master regulator of goblet cell metaplasia, by facilitating its binding to and activation by RhoA, and an E3 ligase PIAS1 is responsible for SUMOylation on K1007. As a result, knockdown of PIAS1 in bronchial epithelia inactivates ROCK2 to attenuate IL-13-induced goblet cell metaplasia, and bronchial epithelial knock-in of ROCK2(K1007R) consistently inactivates ROCK2 to alleviate not only allergen-induced airway inflammation, goblet cell metaplasia, and hyperreactivity, but IL-13-induced goblet cell metaplasia. Together, SUMOylation-mediated ROCK2 activation is an integral component of Rho/ROCK signaling in regulating the pathological conditions of asthma and thus SUMOylation is an additional target for the therapeutic intervention of this disease.
multidisciplinary sciences
What problem does this paper attempt to address?